STRYKER CORP
SYKNYSETrading Snapshot
- Day Range
- $297.00 β $305.26
- 52-Week Range
- $267.00 β $389.33
- Volume (shares)
- 2,325,046
- Avg Volume (shares)
- β
- Shares Outstanding
- 383.6M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $25.12B
- Last Q Revenue
- $6.59B
- P/E Ratio
- 31.4
- P/S Ratio
- 4.5x
- EPS (TTM)
- $9.65
- Dividend Yield
- 1.13%
- Dilution (1yr)
- +0.1%
STRYKER CORP
SYKAbout STRYKER CORP
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
SYK's Q3 earnings may reflect strong hospital equipment demand and cybersecurity recovery, but supply constraints, vascular disruptions and margin pressures remain.

Stryker to participate in the 2026 Jefferies Global Healthcare Conference
Portage, Michigan, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, at the Waldorf Hilton and ME Hotel in London. Spe

It's Too Soon To Upgrade Stryker Corporation
Stryker Corporation remains a global leader in medical technologies, with strong segment breadth and robust product innovation. SYK delivered solid financial growth in H1 2026, with revenue up 6.1% and EBITDA rising to $

Countdown to Stryker (SYK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Stryker (SYK) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metric

Stryker completes acquisition of ZuriMED to enhance its shoulder offering
Portage, Michigan, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the Fiber

Stryker Corporation $SYK Shares Purchased by CMH Wealth Management LLC
CMH Wealth Management LLC raised its stake in shares of Stryker Corporation (NYSE: SYK) by 9.3% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. Th